KPC PharmaceuticalsInc Crescita futura

Future criteri di controllo 3/6

KPC PharmaceuticalsInc prevede che gli utili e i ricavi cresceranno rispettivamente di 28.1% e 13.8% all'anno. Si prevede che l'EPS crescerà di 27.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 12.1% in 3 anni.

Informazioni chiave

28.1%

Tasso di crescita degli utili

27.9%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	18.2%
Tasso di crescita dei ricavi	13.8%
Rendimento futuro del capitale proprio	12.1%
Copertura analitica	Good
Ultimo aggiornamento	22 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Investors Holding Back On KPC Pharmaceuticals,Inc. (SHSE:600422)

Nov 18

Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

Sep 30

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

Sep 11

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Jul 25

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

Jun 25

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

Jun 04

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Mar 28

Previsioni di crescita degli utili e dei ricavi

SHSE:600422 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	10,346	863	168	773	6
12/31/2025	9,495	721	279	646	7
12/31/2024	8,187	542	-33	726	6
9/30/2024	7,550	446	557	609	N/A
6/30/2024	7,487	451	725	780	N/A
3/31/2024	7,646	432	752	811	N/A
12/31/2023	7,703	445	291	356	N/A
9/30/2023	7,700	397	261	333	N/A
6/30/2023	7,825	390	141	222	N/A
3/31/2023	7,828	400	-51	38	N/A
12/31/2022	8,282	383	152	254	N/A
9/30/2022	8,419	446	177	296	N/A
6/30/2022	8,388	392	-23	143	N/A
3/31/2022	8,722	427	-33	177	N/A
12/31/2021	8,254	508	15	252	N/A
9/30/2021	8,321	540	-136	93	N/A
6/30/2021	8,386	564	-22	190	N/A
3/31/2021	8,045	560	-79	118	N/A
1/1/2021	7,717	457	251	410	N/A
9/30/2020	7,779	445	128	361	N/A
6/30/2020	7,788	444	104	393	N/A
3/31/2020	7,910	443	292	564	N/A
12/31/2019	8,120	454	82	430	N/A
9/30/2019	7,817	429	145	452	N/A
6/30/2019	7,473	390	131	376	N/A
3/31/2019	7,237	356	146	402	N/A
12/31/2018	7,102	336	135	352	N/A
9/30/2018	6,797	316	362	568	N/A
6/30/2018	6,507	295	N/A	396	N/A
3/31/2018	6,280	318	N/A	197	N/A
12/31/2017	5,852	330	N/A	283	N/A
9/30/2017	5,637	357	N/A	-5	N/A
6/30/2017	5,330	374	N/A	165	N/A
3/31/2017	5,170	416	N/A	179	N/A
12/31/2016	5,101	407	N/A	311	N/A
9/30/2016	5,161	440	N/A	326	N/A
6/30/2016	5,227	448	N/A	378	N/A
3/31/2016	5,049	433	N/A	491	N/A
12/31/2015	4,916	421	N/A	477	N/A
9/30/2015	4,588	404	N/A	485	N/A
6/30/2015	4,456	367	N/A	391	N/A
3/31/2015	4,361	308	N/A	447	N/A
12/31/2014	4,316	289	N/A	404	N/A
9/30/2014	4,038	264	N/A	338	N/A
6/30/2014	3,860	258	N/A	467	N/A
3/31/2014	3,668	243	N/A	325	N/A
12/31/2013	3,584	232	N/A	242	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 600422 ( 28.1% all'anno) è superiore al tasso di risparmio ( 2.8% ).

Guadagni vs Mercato: Si prevede che gli utili di 600422 ( 28.1% all'anno) cresceranno più rapidamente del mercato CN ( 26.3% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 600422 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 600422 ( 13.8% all'anno) crescerà più lentamente rispetto al mercato CN ( 13.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 600422 ( 13.8% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 600422 sarà basso tra 3 anni ( 12.1 %).

KPC PharmaceuticalsInc Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 7.1% to CN¥25.01

Recent updates

Investors Holding Back On KPC Pharmaceuticals,Inc. (SHSE:600422)

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.22 in 3Q 2023)

KPC Pharmaceuticals,Inc. to Report Q3, 2024 Results on Oct 26, 2024

Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

Investor sentiment improves as stock rises 20%

New minor risk - Earnings quality

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 2Q 2023)

Investor sentiment deteriorates as stock falls 16%

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Dividend increased to CN¥0.20

KPC Pharmaceuticals,Inc. to Report First Half, 2024 Results on Aug 23, 2024

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

Price target decreased by 7.1% to CN¥25.01

KPC Pharmaceuticals,Inc to Report Q1, 2024 Results on Apr 27, 2024

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Full year 2023 earnings: EPS and revenues miss analyst expectations

KPC Pharmaceuticals,Inc to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 16%

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 16%

KPC Pharmaceuticals,Inc to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.12 in 1Q 2020)

New Hope Healthcare Nanjing Investment Center (Limited Partnership) signed an agreement to acquire 3.7% stake in Nanjing Weili Zhibo Biotechnology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for CNY 30 million.

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.60 in FY 2019)

New 90-day low: CN¥8.34

KPC Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day low: CN¥8.38

New 90-day low: CN¥9.12

New 90-day low: CN¥9.54

Third quarter earnings released

KPC Pharmaceuticals, Inc. to Report Q3, 2020 Results on Oct 22, 2020

A group of buyers agreed to acquire 51% stake in Kunming Yinnuo Pharmaceutical Technology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for approximately CNY 170 million.

KPC Pharmaceuticals, Inc. (SHSE:600422) cancelled the acquisition of 30% stake in Zhejiang Holley Nanhu Pharmaceutical Co., Ltd.

First half earnings released

New 90-day high - CN¥11.67

KPC Pharmaceuticals, Inc. to Report First Half, 2020 Results on Aug 21, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita